Why Is Moderna Stock Trading Lower On Wednesday?

Loading... In the presentation slides to the U.S. agency, Moderna Inc MRNA shared safety set data, with a cut-off date of March 8, 2024, based on the median of 18.8 months of follow-up. Vaccine efficacy in the infection with more than two symptoms was 50.3% and 49.9% in disease with three or more symptoms. Efficacy of a single dose of GSK Plc's GSK Arexvy over two calendar years showed vaccine efficacy of 73.3% (W/o season covariate) and 78.6% in severe infection. Last year, GSK's Arexvy and Pfizer's Abrysv ...